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Poster Session II S331donor T cells, as measured by absolute counts (p 5 0.0650). More-
over, Nrf2-/- alloreactive T cells in spleen and MLNs expressed less
a4b7 integrin compared to Nrf+/+ T cells (16.9% versus 31.7%, re-
spectively, p 5 0.0079), indicating impaired homing ability of
Nrf2-/- alloreactive T cells.
Together, we conclude that Nrf-2 is an important mediator of al-
loreactive T cells. These data suggest that Nrf-2 could be a novel tar-
get for preventing GVHD while maintaining GVT activity and
improving overall clinical outcomes.494
NHANES III EQUATIONS FOR PFT INTERPRETATION SIGNIFICANTLY AL-
TERS BOS DIAGNOSES, SEVERITY, AND PROGNOSIS AFTER HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT)
Williams, K.M.1, Hnatiuk, O.2, Steinberg, S.M.3, Mitchell, S.4,
Baird, K.5, Gadalla, S.M.6, Carpenter, A.1, Avila, D.1, Taylor, T.1,
Urban, A.1, Comis, L.E., Blacklock-Schuver, B.1, Gress, R.E.1,
Pavletic, S.Z.1 1National Institutes of Health, Bethesda, MD; 2National
Institutes of Health, Bethesda, MD; 3National Institutes of Health,
Bethesda, MD; 4National Institutes of Health, Bethesda, MD; 5National
Institutes of Health, Bethesda, MD; 6National Institutes of Health,
Bethesda, MD
Bronchiolitis obliterans syndrome (BOS) is a deadly manifestation
of chronic graft-versus-host disease (cGVHD) following HSCT.
The proposed BOS definition includes pulmonary function test
(PFT) parameters of: FEV1\ 75% predicted, FEV1/VC ratio\
0.7, (JAMA 2009) that are determined by reference equations.
NHANES III is the recommended standard, however, older equa-
tions are still used. We sought to determine if the clinical diagnosis
and prognosis of BOS could be predicted by FEV1 and whether the
reference equations influenced these results in a cohort of cGVHD
patients on a NIH protocol. FEV1% predicted and FEV1/FVC for
166 consecutive patients were compared using both NHANES III
and our prior reference equations (Morris/Goldman/Bates-MGB).
The resulting 4 groups were assessed for degree of agreement using
McNemar’s exact test for paired categorical data. Mortality was de-
termined using clinical records and SSDI. Assessing only FEV1%
predicted, 11% (18/166) of patients were classified as normal by
MGB(. 75%), yet abnormal by NHANES III(\75%) while 0/166
were classified as abnormal by MGB(. 75%), yet normal by
NHANES III(\75%) (p\0.0001). Evaluating only FEV1/FVC ra-
tios, 95% (157/166)were concordant by confidence interval.The dis-
cordant ratios were divided evenly between. 0.7 (n5 4) and\0.7 (n
5 5) (p 5 1.00). Using FEV1/VC ratios outside the CI identified 6
more patients who then met criteria for BOS, while 1 was removed
because MGB ratio of\ 0.7 was normal by NHANES III. Using
the amendedBOS definitionwithNHANES III classification, 12 ad-
ditional patients (29%) would have been diagnosed with BOS, and 1
would have been removed from theBOS cohort.NHANES III better
predicted oxygen requirement: 7/8 with FEV1\40% byNHANES
III and 5/8 FEV1\40%byMGB. FEV1 and 2-minute walk velocity
association calculated by either method were weak and comparable
(MGB (r 5 0.25) or NHANES III (r 5 0.24)). For patients with .
1 year of follow-up, 35% of them died (14/40). FEV1\ 35% was
a significant predictor of mortality with either equation (OR 5
20.7, p5 0.001 for NHANES III vs. 18.0, p5 0.01 for MGB equa-
tion).However, theNHANES III equation correctly predicted death
in 9 patients (64%) compared with 6 (42.8%) patients when MGB
equation was used. In conclusion, using NHANES III reference
equationsmarkedly increased the numberof casesmeetingdiagnostic
criteria for BOS and BOS cases categorized using NHANES III
improved prediction of oxygen requirement and survival.495
FEASIBILITY, SAFETY AND EFFICACY OF MARAVIROC, A CCR5 ANTAGO-
NIST, IN GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER REDUCED
INTENSITY CONDITIONED (RIC) ALLOGENEIC STEM CELL TRANSPLANT
(SCT): A PHASE I/II STUDY
Reshef, R., Luger, S.M., Loren, A.W., Frey, N.V., Goldstein, S.C.,
Hexner, E.O., Stadtmauer, E.A., Smith, J., Mick, R., Heitjan, D.F.,
Hoxie, J.A., Emerson, S.G., Vonderheide, R.H., Porter, D.L. University
of Pennsylvania, Philadelphia, PACompelling data implicate the chemokine receptor CCR5 as piv-
otal in the pathogenesis of GvHD through control of lymphocyte
trafficking. We showed that maraviroc (MVC; Selzentry, Pfizer),
a CCR5 antagonist, inhibits in vitro chemotaxis, and hypothesized
that incorporating maraviroc into GvHD prophylaxis will be safe
and limit GvHD without interfering with GvL.
We initiated a phase I/II trial to determine feasibility, safety and
appropriate dose ofMVC, and to determine efficacy when combined
with standard GvHD prophylaxis after RIC SCT. 21 pts received
fludarabine and IV busulfan (6.4 mg/kg) followed by PBSCT from
matched related (6), matched unrelated (12) and 1-antigen mis-
matched unrelated (3) donors. In addition to standard tacrolimus/
methotrexate, MVC at 2 dose levels (150 and 300 mg bid) was given
from day -2 to +30.
The median age was 61 (range 21-74). Indications for SCT were
AML/MDS (10), NHL (4), MF (3), CLL, aplastic anemia, Hodgkin
lymphoma andmyeloma (1 each).MVCwas well tolerated. 3/6 pts at
the 150 mg bid dose level did not reach the targeted Cavg (100 ng/
ml), while the 300 mg bid dose level resulted in adequate Cavg in
6/6 pts and was used as the phase II dose.
The median time to ANC. 500/mLwas 13d (range 10-21) and to
plt . 20k/mL was 13d (range 11-24) with no primary graft failures.
The median whole blood donor chimerism at day 100 was 97%
(range 83-100).
The cumulative incidence of acute GvHD grade II-IV and III-IV
at day 100 is 18% (+/29.8%) and 6% (+/25.9%) respectively in this
high-risk population. Importantly, by day 100 all cases of GvHD
involved only the skin. At a median follow up of 245 days, 4/21 pts
relapsed (2 AML, 1NHL, 1MF) and 7/21 pts died (3 disease-related,
1 GvHD, 1 sepsis, 1 SOS, 1 unrelated).
Biological activity of MVC was assessed in pharmacodynamic as-
says, which test the capacity of patient serum to inhibit CCR5 inter-
nalization and chemotaxis. Patient serum from multiple time points
prevented internalization of CCR5 by RANTES. In vitro chemo-
taxis of normal donor T-cells in response to RANTES was signifi-
cantly impaired following incubation in patient serum from day
0 of transplant (on MVC) as compared to day 60 (off MVC).
Though the phase II portion of the trial is ongoing, we conclude
that MVC 300mg bid was well tolerated and biologically active.
Patients exhibited limited GvHD without excessive relapses or en-
graftment failures. Inhibition of lymphocyte trafficking represents
a promising strategy to reduce acute GvHD.496
AUGMENTED REGULATORY T CELL RESPONSE AFTER PHOTOCHEMICAL
TREATMENT ALLEVIATES ACUTE GRAFT-VERSUS HOST DISEASE AND IM-
PROVES SURVIVAL
Kanathezhath, B.1,2, Stanislaus, S.2, Kaplan, J.2, Larkin, S.2,
Kuypers, F.2, Walters, M.1,2 1Children’s Hospital & Research Institute
Oakland, Oakland, CA; 2Children’s Hospital Oakland Research Institute,
Oakland, CA
Graft-versus-Host disease (GVHD) causes significant morbid-
ity and mortality after allogeneic transplantation. Acute GVHD
early post transplantation is heralded by a cytokine storm induced
by a dominant T helper type 1(Th1) response, which damages
host tissues like skin, gut, liver and lungs. We hypothesized that
co-transplantation of photochemically (S-59) treated T cells mod-
ulates T cell effecter subsets and their cytokine milieu, and
thereby reduces acute GVHD. To this end, we transplanted
whole bone marrow cells in a major histocompatibility complex
(MHC) antigen mismatched murine model using marrow with
T cells from C57BL/6J/ AKR (acute GVHD model), with
and without S-59 treatment. We observed equivalent elevation
of CD4+Th1 (IL-2 and IFN-g), cytotoxic CD8+ (FAS, IFN-g
and TNF-a) and CD4+Th2 (IL-4, IL-5, IL-6, IL-13) cytokines
in recipients of both groups during the first week after transplan-
tation. While the Th1 cytokines persisted as long as 10 days after
transplantation, there was a shift to a regulatory T cell (Treg) cy-
tokine profile (Transforming growth factor b [TGF-b] and IL-10)
in the group that received the S-59 treated T cells. TGF-b and
IL-10 levels were higher in the peripheral blood and bone mar-
row of the study group compared to controls. This was accompa-
nied by the appearance of FoxP3High CD4+ CD25+ Tregs in the
S332 Poster Session IIspleen and CD4+ Th17 cytokine (IL-17) elevation in the thymic
compartment of recipients that received S-59 treated T cells
(mean-28.44pg/ml versus 1.45pg/ml, p 5 0.0059). In-vivo track-
ing of S-59 treated T cells demonstrated the disappearance of
these cells in the peripheral blood, spleen, bone marrow and thy-
mus within 48 hours of transplantation. Nonetheless, we noted
that recipients of S-59 treated T cells had significantly less acute
GVHD and better overall survival (p 5 0.0001). In-vitro co-cul-
tures of stem cells (HSC) with S-59 T cells demonstrated signif-
icant increase in multilineage CFU formation(p \ 0.0001). In
summary, our experiments indicate that there is an initial domi-
nance of inflammatory and CD4 Th1 cytokines immediately
post transplantation. Co-transplantation of S-59 treated T cells
shifts the effector CD4 T cell profile to resemble a Treg pheno-
type. Thus, S-59 treated T cells appear to exert an important
immunomodulatory effect to ameliorate GVHD and improve
survival after MHC-mismatched allogeneic transplantation. In
addition these T cells exert a direct proliferative effect on the
HSCs.
Table 1. Cytokine Profile
Peripheral blood Bone marrow ThymocyteTGF-b [S59] 8482.7 pg/ml 7062.1pg/ml 2926.9pg/ml
TGF-b [control] 1.1pg/ml 301.55 pg/ml 46.5 pg/ml
IL-10 [S59] 419.0 pg/ml 174.0 30.4pg/ml
IL-10 [control] <1pg/ml 82.1pg/ml 33.44pg/mlp value- * 0.0001, **0.0006497
SIROLIMUS INDUCES COMPLETE REMISSION OF ACUTE GRAFT-VERSUS-
HOST DISEASE WITHOUT SYSTEMIC GLUCOCORTICOIDS
Pidala, J., Tomblyn, M., Nishihori, T., Perkins, J., Field, T., Ayala, E.,
Alsina, M., Ochoa, L., Locke, F., Perez, L., Fernandez, H., Anasetti, C.
Moffitt Cancer Center, Tampa, FL
While glucocorticoids have been considered essential in pri-
mary therapy of acute graft-versus-host disease (aGVHD), com-
plete remission from aGVHD is achieved in the minority of
cases. Sirolimus is a potent immunosuppressive agent which
may provide a novel approach to primary aGVHD therapy. In
a retrospective analysis, we examined the efficacy of sirolimus
as sole primary therapy for aGVHD. A total of 32 allogeneic
peripheral blood stem cell recipients (78% unrelated donors,
16% with 1-2 antigen mismatch) with biopsy confirmed aGVHD
were treated with sirolimus at a median of 30 days (range 15 –
106) after allogeneic hematopoietic cell transplantation (HCT).
Median age was 60 years (range 28–73). Patients were at high
risk for relapse of primary malignancy, with 23/32 not in remis-
sion at time of HCT. Sirolimus was delivered orally to achieve
serum levels of 4-12ng/mL. Therapeutic serum levels of siroli-
mus were achieved in all cases, including those with GI involve-
ment. All patients had tacrolimus based aGVHD prophylaxis;
target tacrolimus level was reduced to 3-7ng/mL once sirolimus
was initiated. Complete remission (CR) was defined as complete
resolution of all aGVHD manifestations sustained for at least 4
weeks without the addition of glucocorticoids or other systemic
immune suppressive agents. At time of primary sirolimus therapy,
53% had skin involvement, 66% GI, and 16% hepatic. Overall
grade was 1 (12%), 2 (75%), and 3 (13%). Sixteen (50%) achieved
sustained CR of aGVHD following sirolimus treatment. CR did
not significantly differ according to organ involvement or overall
aGVHD severity. With median follow up time of 16 months
(range 6-26 months), one year OS was 56% (95% CI 38-74%).
Accounting for competing risk, the cumulative incidence of
relapse at one year was 37% (23-60%), and NRM was 20%
(10-42%). The cumulative incidence of any grade chronic
GVHD per NIH consensus criteria was 55% (39-79%). Throm-
botic microangiopathy occurred in three cases, which responded
to dose reduction or elimination of calcineurin inhibitor.
Sirolimus demonstrates activity that rivals that of high dose
glucocorticoids in the primary therapy of aGVHD.498
RAPAMYCIN DELAYS XENOGENEIC ACUTE GRAFT VERSUS HOST DISEASE
(AGVHD) IN NOD/SCID/IL2RgNULL (NSG) MICE: IMPACT OF REGULA-
TORY T CELLS
Bruck, F., Baron, F., Dubois, S., Briquet, A., Hanon-Absil, M., Belle, L.,
Menten, C., Beguin, Y., Humblet-Baron, S. University of Liege, Liege,
Liege, Belgium
Background: Rapamycin (RAPA), a mTOR inhibitor also termed
sirolimus, is a potent immunosuppressive drug which might induce
tolerance by inhibiting activated T cells but not regulatory (Treg)
T cells. The aims of the current study were to establish a humanized
model of aGVHD in NSG mice, and to assess the impact of RAPA
and Treg infusion/depletion on morbidity from xenogeneic
aGVHD.
Methods andResults:Wefirst assessed the impact of the dose of IV
infused human PBMC on GVHD mortality. After 2.5 Gy TBI irra-
diation NSG mice received 5105 (n 5 5), 1106 (n 5 5), 2106
(n 5 5) or 3106 (n 5 5) human PBMC. Mean survivals in each
group were 3667 days, 3066 days, 2465 days and 1661 days,
respectively. At time of death, mice presented clinical symptoms of
aGVHDsuch as weight loss higher than. 20%, and showedmassive
CD3+ humanT cells infiltration of their marrows, livers, spleens and
lungs. Based on these results, we decided to use 2106 PBMC for
further experiments. We then investigated whether injection of
RAPA or PBMC supplemented in Treg could mitigate aGVHD in
this model. After receiving 2.5 Gy TBI NSGmice were transplanted
with 2106 PBMC and i.p. PBS (control arm), with 2106 PBMC
and i.p. RAPA (rapa arm), with 2106 PBMC depleted in Treg
and i.p. RAPA (Treg-depleted arm), or with 2106 PBMC supple-
mented in Treg (1Treg:8PBMC) and i.p. PBS (Treg arm). Mice
were daily monitored for survival and weighed at least once a week
until sacrifice. Median survival was higher in the RAPA arm than
in the control arm (96 vs. 24 days, P \ 0.01), while mice given
Treg-depleted PBMC plus RAPA had a median survival of 48 days
(P\ 0.01 in comparison with the rapa arm). In contrast, mice in
the Treg arm had a median survival of 71 days (P\0.01 in compar-
ison with the control arm).
Conclusions: In summary, our data indicate that i.v. injection of
2106 PBMC into irradiatedNSGmice induced a severe xenogeneic
aGVHD. RAPA administration increased survival but this effect was
greatly affected byTreg depletion suggesting that RAPA administra-
tion prevented death fromGVHDat least in part by promotingTreg.499
STAT1 DEFICIENCY FAILS TO PROTECT AGAINST MURINE CHRONIC
GVHD
Foley, J.E., Amarnath, S., Felizardo, T.C., He, A., Fowler, D.H.
National Cancer Institute, Bethesda, MD
Donor Th1 cells, which play a key role in promoting acute
GVHD, may also contribute to chronic GVHD. To further charac-
terize the role of Th1 cells in cGVHD, we used a model developed
by the Drobyski Lab whereby acute GVHD is initiated (B6 0
BALB/c BMT; 21-day transplant interval), with subsequent adoptive
transfer of post-BMT B6 T cells into syngeneic, immune-deficient
hosts (B6129s7-Rag1; 45-day observation interval) for induction of
auto-reactive, cGVHD. Because STAT1 is the signaling pathway
for the Th1-polarizing cytokines IFN-a and IL-12, we used
STAT1-deficient (KO) donor T cells to assess whether Th1 cell
deficiency might yield reduced cGVHD; other transplant cohorts
received T cells that were either wild-type (WT), STAT3-KO
(loss of Th17 function), or STAT6-KO (loss of Th2 function). Clin-
ical signs of acute GVHD (weight loss, hunched posture) was severe
in WT, mild in STAT3-KO, and STAT6-KO T cells; in contrast,
STAT1-KO T cell recipients showed no signs of acute GVHD.
Chronic GVHD, which was manifested by weight loss and extensive
skin disease (erythematous, scaling rash with alopecia; . 50% body
surface area), occurred in 100% of recipients of WT and STAT1-
KOT cells (5/5 and 10/10 cases, respectively); by comparison, exten-
sive skin disease was not observed in recipients of STAT3-KO or
STAT6-KO T cells (0/9 and 0/5 cases, respectively). As such,
STAT1-deficiency appeared to reduce acute GVHDbut not chronic
GVHD. Further experiments were performed at the end of the
cGVHD observation interval to confirm that recipients of
